Skip to main content
SpringerLink
Log in

Primary Hyperparathyroidism in MEN2 Syndromes

  • Chapter
  • First Online:
Medullary Thyroid Carcinoma

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 204))

Abstract

One of the components of trethe classical form of MEN2 syndromes is primary hyperparathyroidism (PHP). It occurs in 20–30 % of the typical MEN2A syndrome. The prevalence is more rare in gene carriers as these frequently have familial MTC only. PHP is diagnosed more frequently in association with the exon 11, codon 634 mutation of the ret gene—so there is phenotype/genotype correlation. The clinical manifestations of PHP in MEN2 are usually mild and the peak age of diagnosis after the 3rd decade. The treatment is surgical excision of the enlarged gland(s). Although there can be multigland disease in the parathyroids, it is frequently the case that both hyperplasia and adenoma may coexist, or even a single adenoma may be found during the investigation and finally during the operation. Patients with MEN2 syndromes should be screened for PHP with serum calcium measurements. The intensity of the screening should be higher in those carrying the ret mutations most frequently associated with this manifestation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Alevizaki M (2013) Management of hyperparathyroidism (PHP) in MEN2 syndromes in Europe. Thyroid Res 6(Suppl 1):S10

    Article  PubMed Central  PubMed  Google Scholar 

  • Carling T, Udelsman R (2005) Parathyroid surgery in familial hyperparathyroid disorders. J Int Med 257:27–37

    Article  CAS  Google Scholar 

  • Dimas S, Michas S, Christakis I, Augoustis C, Alevizaki M (2012) Minimally invasive parathyroidectomy in patients with previous neck surgery. Hormones (Athens) 11:160–165

    Article  Google Scholar 

  • Dotzenrath C, Cupisti K, Goretzki PE, Yang Q, Simon D, Ohmann C, Roher HD (2001) Long-term biochemical results after operative treatment of primary hyperparathyroidism associated with multiple endocrine neoplasia types I and IIa: is a more or less extended operation essential? Eur J Surg 167:173–178

    Article  CAS  PubMed  Google Scholar 

  • Elisei R, Romei C, Renzini G, Bottici V, Cosci B, Molinaro E, Agate L, Cappagli V, Miccoli P, Berti P, Faviana P, Ugolini C, Basolo F, Vitti P, Pinchera A (2012) The timing of total thyroidectomy in ret gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center. J Clin Endocrinol Metab 97:426–435

    Article  CAS  PubMed  Google Scholar 

  • Frank-Raue K, Rybicki LA, Erlic Z, Schweizer H, Winter A, Milos I, Toledo SP, Toledo RA, Tavares MR, Alevizaki M, Mian C, Siggelkow H, Hufner M, Wohllk N, Opocher G, Dvorakova S, Bendlova B, Czetwertynska M, Skasko E, Barontini M, Sanso G, Vorlander C, Maia AL, Patocs A, Links TP, de Groot JW, Kerstens MN, Valk GD, Miehle K, Musholt TJ, Biarnes J, Damjanovic S, Muresan M, Wuster C, Fassnacht M, Peczkowska M, Fauth C, Golcher H, Walter MA, Pichl J, Raue F, Eng C, Neumann HP (2011) Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline ret mutations located in exon 10. Hum Mutat 32:51–58

    Article  CAS  PubMed  Google Scholar 

  • Herfarth KK, Bartsch D, Doherty GM, Wells SA Jr, Lairmore TC (1996) Surgical management of hyperparathyroidism in patients with multiple endocrine neoplasia type 2A. Surgery 120:966–973 (discussion 973–974)

    Article  CAS  PubMed  Google Scholar 

  • Karga HJ, Karayianni MK, Linos DA, Tseleni SC, Karaiskos KD, Papapetrou PD (1998) Germ line mutation analysis in families with multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma. Eur J Endocrinol 139:410–415

    Article  CAS  PubMed  Google Scholar 

  • Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA Jr (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565–612

    Article  PubMed  Google Scholar 

  • Kraimps JL, Denizot A, Carnaille B, Henry JF, Proye C, Bacourt F, Sarfati E, Dupond JL, Maes B, Travagli JP, Boneu A, Roger P, Houdent C, Barbier J, Modigliani E (1996) Primary hyperparathyroidism in multiple endocrine neoplasia type IIa: retrospective French multicentric study. Groupe d’Etude des Tumeurs a Calcitonine (GETC, French Calcitonin Tumors Study Group), French Association of Endocrine Surgeons. World J Surg 20:808–812 (discussion 812–813)

    Article  CAS  PubMed  Google Scholar 

  • Machens A, Lorenz K, Dralle H (2013a) Peak incidence of pheochromocytoma and primary hyperparathyroidism in multiple endocrine neoplasia 2: need for age-adjusted biochemical screening. J Clin Endocrinol Metab 98:E336–E345

    Article  CAS  PubMed  Google Scholar 

  • Machens A, Lorenz K, Sekulla C, Hoppner W, Frank-Raue K, Raue F, Dralle H (2013b) Molecular epidemiology of multiple endocrine neoplasia 2: implications for RET screening in the new millenium. Eur J Endocrinol 168:307–314

    Article  CAS  PubMed  Google Scholar 

  • Magalhaes PK, Antonini SR, de Paula FJ, de Freitas LC, Maciel LM (2011) Primary hyperparathyroidism as the first clinical manifestation of multiple endocrine neoplasia type 2A in a 5-year-old child. Thyroid 21:547–550

    Article  PubMed  Google Scholar 

  • Marcocci C, Chanson P, Shoback D, Bilezikian J, Fernandez-Cruz L, Orgiazzi J, Henzen C, Cheng S, Sterling LR, Lu J, Peacock M (2009) Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab 94:2766–2772

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Mian C, Barollo S, Zambonin L, Pennelli G, Bernante P, Pelizzo MR, Nacamulli D, Mantero F, Girelli ME, Opocher G (2009) Characterization of the largest kindred with MEN2A due to a Cys609Ser RET mutation. Fam Cancer 8:379–382

    Article  CAS  PubMed  Google Scholar 

  • O’Riordain DS, O’Brien T, Grant CS, Weaver A, Gharib H, van Heerden JA (1993) Surgical management of primary hyperparathyroidism in multiple endocrine neoplasia types 1 and 2. Surgery 114:1031–1037 (discussion 1037–1039)

    PubMed  Google Scholar 

  • Raue F, Frank-Raue K (2009) Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management. Hormones (Athens) 8:23–28

    Article  Google Scholar 

  • Raue F, Kraimps JL, Dralle H, Cougard P, Proye C, Frilling A, Limbert E, Llenas LF, Niederle B (1995) Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. J Intern Med 238:369–373

    Article  CAS  PubMed  Google Scholar 

  • Romei C, Cosci B, Renzini G, Bottici V, Molinaro E, Agate L, Passannanti P, Viola D, Biagini A, Basolo F, Ugolini C, Materazzi G, Pinchera A, Vitti P, Elisei R (2011) ret genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC). Clin Endocrinol (Oxf) 74:241–247

    Article  CAS  Google Scholar 

  • Sarika L, Papathoma A, Garofalaki M, Saltiki K, Pappa T, Pazaitou-Panayiotou K, Anastasiou E, Alevizaki M (2015) Genetic screening of patients with Medullary Thyroid Cancer (MTC) in a referral center in Greece during the past two decades. Eur J Endocrinol

    Google Scholar 

  • Scholten A, Schreinemakers JM, Pieterman CR, Valk GD, Vriens MR, Borel Rinkes IH (2011) Evolution of surgical treatment of primary hyperparathyroidism in patients with multiple endocrine neoplasia type 2A. Endocr Pract 17:7–15

    Article  PubMed  Google Scholar 

  • Schuffenecker I, Virally-Monod M, Brohet R, Goldgar D, Conte-Devolx B, Leclerc L, Chabre O, Boneu A, Caron J, Houdent C, Modigliani E, Rohmer V, Schlumberger M, Eng C, Guillausseau PJ, Lenoir GM (1998) Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the ret proto-oncogene. Groupe D’etude des Tumeurs a Calcitonine. J Clin Endocrinol Metab 83:487–491

    CAS  PubMed  Google Scholar 

  • Steiner AL, Goodman AD, Powers SR (1968) Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing’s disease: multiple endocrine neoplasia, type 2. Medicine (Baltimore) 47:371–409

    Article  CAS  Google Scholar 

  • Uchino S (2012) Multiple endocrine neoplasia type 2 in Japan: large-scale analysis of data from the MEN consortium of Japan. Nihon Geka Gakkai Zasshi 113:362–367

    PubMed  Google Scholar 

  • Valdes N, Navarro E, Mesa J, Casteras A, Alcazar V, Lamas C, Tebar J, Castano L, Gaztambide S, Forga L (2015) ret Cys634Arg mutation confers a more aggressive multiple endocrine neoplasia type 2A phenotype than Cys634Tyr mutation. Eur J Endocrinol 172:301–307

    Article  CAS  PubMed  Google Scholar 

  • Yoshida S, Imai T, Kikumori T, Wada M, Sawaki M, Takada H, Yamada T, Sato S, Sassa M, Uchida H, Watanabe R, Kagawa C, Nakao A, Kiuchi T (2009) Long term parathyroid function following total parathyroidectomy with autotransplantation in adult patients with MEN2A. Endocr J 56:545–551

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrine Unit, Department Medical Therapeutics, Alexandra Hospital, Athens University School of Medicine, 80, Vassilissis Sofias Ave, Athens, 11528, Greece

    Maria Alevizaki & Katerina Saltiki

Authors
  1. Maria Alevizaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katerina Saltiki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Alevizaki .

Editor information

Editors and Affiliations

  1. Endocrine Practice and Molecular Laboratory, Medical Faculty, University of Heidelberg , Heidelberg, Germany

    Friedhelm Raue

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Alevizaki, M., Saltiki, K. (2015). Primary Hyperparathyroidism in MEN2 Syndromes. In: Raue, F. (eds) Medullary Thyroid Carcinoma. Recent Results in Cancer Research, vol 204. Springer, Cham. https://doi.org/10.1007/978-3-319-22542-5_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-22542-5_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-22541-8

  • Online ISBN: 978-3-319-22542-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation